IRMD - iRadimed Corp Stock Price, Fair Value and News

41.99USD-0.66 (-1.55%)Delayed

Market Summary

USD41.99-0.66

Delayed

-1.55%

IRMD Stock Price

View Fullscreen

IRMD RSI Chart

IRMD Valuation

Market Cap

531.8M

Price/Earnings (Trailing)

29.67

Price/Sales (Trailing)

7.86

EV/EBITDA

20.76

Price/Free Cashflow

46.7

IRMD Price/Sales (Trailing)

IRMD Profitability

Operating Margin

76.57%

EBT Margin

33.44%

Return on Equity

23.55%

Return on Assets

20.36%

Free Cashflow Yield

2.14%

IRMD Fundamentals

IRMD Revenue

Revenue (TTM)

67.7M

Rev. Growth (Yr)

13.72%

Rev. Growth (Qtr)

0.84%

IRMD Earnings

Earnings (TTM)

17.9M

Earnings Growth (Yr)

21.45%

Earnings Growth (Qtr)

-8.88%

Breaking Down IRMD Revenue

Last 7 days

-3.7%

Last 30 days

3.8%

Last 90 days

-7.7%

Trailing 12 Months

-8.3%

How does IRMD drawdown profile look like?

IRMD Financial Health

Current Ratio

9.44

IRMD Investor Care

Shares Dilution (1Y)

0.55%

Diluted EPS (TTM)

1.41

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	67.7M	0	0	0
2023	56.5M	59.9M	63.0M	65.6M
2022	44.9M	47.8M	50.3M	53.3M
2021	32.3M	35.3M	38.5M	41.8M
2020	38.8M	36.3M	34.1M	31.7M
2019	31.8M	33.6M	36.0M	38.5M
2018	25.0M	26.9M	28.8M	30.4M
2017	28.7M	24.4M	22.4M	23.1M
2016	33.6M	35.8M	35.3M	32.5M
2015	19.1M	22.0M	26.4M	31.6M
2014	12.4M	13.5M	14.6M	15.7M
2013	0	0	0	11.3M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of iRadimed Corp

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Dec 27, 2023	susi roger e.	sold	-232,547	46.5094	-5,000	ceo, president, chairman
Dec 26, 2023	susi roger e.	sold	-230,000	46.00	-5,000	ceo, president, chairman
Dec 21, 2023	susi roger e.	gifted	-	-	-300,000	ceo, president, chairman
Dec 19, 2023	susi roger e.	sold	-225,696	45.1393	-5,000	ceo, president, chairman
Dec 18, 2023	susi roger e.	sold	-220,402	44.0805	-5,000	ceo, president, chairman
Dec 14, 2023	hawkins james b	acquired	42,085	9.84	4,277	-
Dec 14, 2023	hawkins james b	sold	-190,687	44.5843	-4,277	-
Dec 13, 2023	hawkins james b	acquired	51,355	9.84	5,219	-
Dec 13, 2023	hawkins james b	sold	-223,540	42.8319	-5,219	-
Dec 12, 2023	susi roger e.	sold	-214,113	42.8226	-5,000	ceo, president, chairman

Which funds bought or sold IRMD recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	added	1.96	-20,790	356,407	-%
May 16, 2024	COMERICA BANK	added	2,151	60,352	63,390	-%
May 15, 2024	MILLENNIUM MANAGEMENT LLC	reduced	-5.51	-606,442	4,271,380	-%
May 15, 2024	CITADEL ADVISORS LLC	added	56.99	436,686	1,396,810	-%
May 15, 2024	Aristides Capital LLC	added	87.11	343,956	812,627	0.30%
May 15, 2024	OCCUDO QUANTITATIVE STRATEGIES LP	sold off	-100	-202,175	-	-%
May 15, 2024	Soleus Capital Management, L.P.	reduced	-43.78	-14,624,900	15,908,100	1.18%
May 15, 2024	Man Group plc	reduced	-77.37	-944,490	250,567	-%
May 15, 2024	TWO SIGMA INVESTMENTS, LP	added	0.44	-102,048	1,372,180	-%
May 15, 2024	ALGERT GLOBAL LLC	reduced	-5.29	-89,000	640,000	0.03%

Are Funds Buying or Selling IRMD?

Are funds buying IRMD calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own IRMD

No. of Funds

Unveiling iRadimed Corp's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	susi roger e.	36.4%	4,587,950	SC 13G/A
Feb 12, 2024	nine ten capital management llc	6.3%	799,366	SC 13G/A
Feb 09, 2024	blackrock inc.	5.2%	651,948	SC 13G
Feb 02, 2024	soleus capital master fund, l.p.	5.1%	641,706	SC 13G/A
Feb 14, 2023	soleus capital master fund, l.p.	5.9%	742,004	SC 13G/A
Feb 13, 2023	renaissance technologies llc	4.73%	594,312	SC 13G/A
Feb 10, 2023	nine ten capital management llc	6.2%	781,766	SC 13G/A
Sep 01, 2022	soleus capital master fund, l.p.	5.1%	646,411	SC 13G
Feb 11, 2022	renaissance technologies llc	5.62%	693,312	SC 13G/A
Feb 09, 2022	nine ten capital management llc	5.9%	730,659	SC 13G/A

Recent SEC filings of iRadimed Corp

View All Filings

Date Filed	Form Type	Document
May 09, 2024	ARS	ARS
May 08, 2024	EFFECT	EFFECT
May 06, 2024	S-3/A	S-3/A
May 03, 2024	DEFA14A	DEFA14A
May 02, 2024	8-K	Current Report
May 02, 2024	10-Q	Quarterly Report
Apr 29, 2024	DEF 14A	DEF 14A
Apr 03, 2024	S-3	S-3
Mar 01, 2024	10-K	Annual Report
Feb 13, 2024	SC 13G/A	Major Ownership Report

Peers (Alternatives to iRadimed Corp)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	181.0B	40.3B	-1.75%	-4.07%	32.18	4.49	-2.84%	-3.08%
BDX	68.3B	19.7B	1.78%	-6.05%	51.24	3.46	4.82%	-17.56%
ALGN	20.4B	3.9B	-9.57%	-7.50%	44.2	5.22	5.72%	46.72%
BAX	18.0B	14.9B	-10.73%	-18.01%	6.79	1.21	2.98%	207.68%
MID-CAP
ATR	9.8B	3.5B	6.68%	24.08%	31.27	2.76	6.16%	35.06%
HSIC	9.6B	12.5B	6.31%	-2.51%	24.63	0.77	-0.61%	-18.83%
BIO	8.4B	2.6B	1.13%	-22.65%	-26.02	3.22	-6.25%	-68.62%
XRAY	5.9B	3.9B	-6.79%	-30.12%	-62.84	1.49	0.23%	91.03%
AXNX	3.4B	387.1M	0.52%	31.17%	-216.3	8.9	30.82%	65.57%
PDCO	2.3B	6.6B	0.19%	-5.50%	11.93	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	5.94%	-10.00%	-1.91	0.41	7.94%	-1661.78%
ANIK	376.6M	169.3M	-1.13%	-2.23%	-4.9	2.23	7.49%	-244.90%
ANGO	241.9M	324.0M	-4.58%	-37.15%	-1.26	0.75	-3.19%	-337.41%
APYX	56.1M	50.5M	22.73%	-73.49%	-2.46	1.11	14.25%	-10.06%
AEMD	1.1M	3.7M	-71.13%	32.26%	-0.09	0.29	5.77%	8.23%

iRadimed Corp News

Latest updates

iRadimed Corp Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	0.8%	17,598	17,452	16,505	16,130	15,475	14,864	13,407	12,722	12,311	11,873	10,907	9,810	9,224	8,546	7,699	6,795	8,678	10,891	9,963	9,226	8,438
Cost Of Revenue	4.2%	4,210	4,039	3,667	3,944	3,754	3,643	2,865	2,582	2,931	2,623	2,502	2,478	2,162	2,107	1,958	1,865	2,214	2,742	2,168	1,858	2,048
Gross Profit	-0.2%	13,388	13,413	12,837	12,186	11,721	11,220	10,543	10,140	9,380	9,250	8,406	7,332	7,062	6,439	5,741	4,930	6,464	8,149	7,795	7,367	6,390
Operating Expenses	4.7%	8,639	8,253	6,932	7,223	7,714	6,967	6,410	5,973	6,305	6,140	5,319	5,488	5,285	5,788	4,956	7,859	5,727	5,910	5,276	4,992	4,876
S&GA Expenses	-75.3%	821	3,329	2,864	2,948	3,000	3,665	3,037	2,908	3,070	3,121	2,586	2,470	2,379	3,069	2,282	2,374	2,434	2,562	2,297	2,200	2,111
R&D Expenses	488.4%	3,827	650	453	962	794	605	492	663	519	495	481	454	476	513	477	483	430	379	370	331	353
EBITDA Margin	0.9%	0.35*	0.34*	0.33*	0.31*	0.32*	0.32*	0.32*	0.32*	0.28*	0.27*	0.23*	0.18*	-	-	-	-	-	-	-	-	-
Income Taxes	-3.1%	1,107	1,142	1,341	1,119	944	1,030	810	939	573	-779	518	388	384	27.00	-280	-798	-933	-887	174	365	-239
Earnings Before Taxes	-7.7%	5,244	5,682	6,409	5,298	4,350	4,704	4,237	4,180	3,060	3,113	3,094	1,857	1,771	665	794	-2,911	836	2,354	2,629	2,454	1,606
EBT Margin	0.8%	0.33*	0.33*	0.33*	0.31*	0.31*	0.30*	0.29*	0.28*	0.25*	0.24*	0.19*	0.14*	-	-	-	-	-	-	-	-	-
Net Income	-8.9%	4,137	4,540	5,067	4,180	3,406	3,674	3,427	3,241	2,487	3,893	2,576	1,470	1,387	637	1,075	-2,112	1,769	3,242	2,455	2,089	1,846
Net Income Margin	1.0%	0.26*	0.26*	0.26*	0.25*	0.24*	0.24*	0.26*	0.26*	0.23*	0.22*	0.16*	0.13*	-	-	-	-	-	-	-	-	-
Free Cashflow	6.9%	3,613	3,381	1,085	3,309	-1,749	2,781	3,746	1,451	1,243	3,275	3,228	3,462	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-4.5%	88.00	92.00	87.00	81.00	76.00	86.00	80.00	76.00	72.00	83.00	78.00	76.00	72.00	71.00	70.00	69.00	68.00	67.00	63.00	57.00	54.00
Current Assets	-5.4%	72.00	76.00	72.00	66.00	61.00	77.00	72.00	68.00	66.00	76.00	72.00	69.00	65.00	64.00	63.00	60.00	61.00	59.00	56.00	50.00	47.00
Cash Equivalents	-9.3%	45.00	50.00	47.00	46.00	43.00	58.00	56.00	52.00	50.00	62.00	58.00	55.00	51.00	50.00	48.00	45.00	45.00	43.00	39.00	32.00	30.00
Inventory	-1.0%	13.00	13.00	12.00	8.00	6.00	5.00	5.00	5.00	4.00	4.00	4.00	4.00	5.00	4.00	5.00	5.00	4.00	4.00	4.00	4.00	4.00
Net PPE	1.8%	9.00	9.00	9.00	9.00	9.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
Liabilities	-42.6%	12.00	21.00	13.00	12.00	11.00	12.00	10.00	10.00	10.00	11.00	11.00	11.00	9.00	10.00	10.00	10.00	10.00	11.00	11.00	10.00	10.00
Current Liabilities	-53.4%	8.00	16.00	8.00	8.00	7.00	9.00	6.00	6.00	6.00	7.00	6.00	6.00	5.00	5.00	5.00	5.00	5.00	6.00	6.00	5.00	5.00
Shareholder's Equity	6.6%	76.00	71.00	75.00	69.00	64.00	74.00	70.00	66.00	63.00	72.00	68.00	65.00	63.00	61.00	61.00	58.00	58.00	56.00	52.00	47.00	45.00
Retained Earnings	9.6%	47.00	43.00	47.00	42.00	37.00	47.00	44.00	40.00	37.00	47.00	43.00	41.00	39.00	38.00	37.00	36.00	38.00	36.00	33.00	31.00	29.00
Additional Paid-In Capital	2.0%	29.00	28.00	28.00	27.00	27.00	26.00	26.00	26.00	26.00	25.00	25.00	24.00	24.00	24.00	24.00	22.00	20.00	19.00	19.00	17.00	16.00
Shares Outstanding	0.0%	13.00	13.00	13.00	13.00	13.00	13.00	13.00	13.00	13.00	12.00	12.00	12.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	379	-	-	-	242	-	-	-	185	-	-	-	146	-	-	-	107	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-0.7%	3,883	3,912	1,393	3,514	4,646	3,039	3,938	1,639	1,426	3,366	3,378	3,571	943	2,496	1,334	791	1,197	3,949	3,138	2,480	665
Share Based Compensation	14.1%	629	551	534	568	534	427	393	121	453	392	777	-57.56	348	318	417	2,659	569	549	456	468	382
Cashflow From Investing	24.3%	-478	-632	-439	-378	-6,557	-471	-556	78.00	-424	260	-220	783	-173	301	-110	287	-230	935	1,369	339	557
Cashflow From Financing	-2961.8%	-8,039	-262	-31.37	-89.77	-13,272	-198	52.00	-5.72	-12,554	2.00	54.00	4.00	-36.25	-277	868	-256	188	-39.95	1,708	-82.20	434
Dividend Payments	-	7,976	-	-	-	13,223	-	-	-	12,559	-	-	-	-	-	-	-	-	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

IRMD Income Statement

2024-03-31

CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME
Revenue	$ 17,598,119	$ 15,475,083
Cost of revenue	4,210,396	3,753,635
Gross profit	13,387,723	11,721,448
Operating expenses:
General and administrative	3,991,211	3,920,510
Research and development	3,827,165	2,999,976
Sales and marketing	821,000	793,716
Total operating expenses	8,639,376	7,714,202
Income from operations	4,748,347	4,007,245
Other income, net	495,154	342,409
Income before provision for income taxes	5,243,501	4,349,655
Provision for income tax expense	1,106,968	943,589
Net income	$ 4,136,533	$ 3,406,066
Net income per share:
Basic (in dollars per share)	$ 0.33	$ 0.27
Diluted (in dollars per share)	$ 0.32	$ 0.27
Weighted average shares outstanding:
Basic (in shares)	12,662,526	12,593,033
Diluted (in shares)	12,749,973	12,686,699

IRMD Balance Sheet

2024-03-31

CONDENSED BALANCE SHEETS - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 45,126,676	$ 49,762,198
Accounts receivable, net of allowance for credit losses of $330,628 as of March 31, 2024, and $368,835 as of December 31, 2023	13,026,802	12,224,273
Inventory, net	12,696,160	12,821,194
Prepaid expenses and other current assets	1,035,964	1,193,447
Total current assets	71,885,602	76,001,112
Property and equipment, net	9,451,903	9,288,625
Intangible assets, net	2,669,858	2,519,053
Operating lease right-of-use asset	1,938,427	2,043,043
Deferred tax asset, net	1,883,689	2,122,816
Other assets	184,701	181,449
Total assets	88,014,180	92,156,098
Current liabilities:
Accounts payable	1,285,366	1,857,091
Accrued payroll and benefits	2,144,221	2,775,103
Other accrued taxes	136,538	103,241
Warranty reserve	115,030	117,463
Deferred revenue	2,338,414	2,570,407
Dividend payable		7,975,997
Current portion of operating lease liabilities	418,814	427,963
Other current liabilities	250,000	250,000
Accrued income taxes	928,287	250,041
Total current liabilities	7,616,670	16,327,306
Deferred revenue, non-current	2,756,435	2,793,548
Operating lease liabilities, non-current	1,519,613	1,615,080
Total liabilities	11,892,718	20,735,934
Stockholders' equity:
Common stock; $0.0001 par value; 31,500,000 shares authorized; 12,664,185 shares issued and outstanding as of March 31, 2024, and 12,660,313 shares issued and outstanding as of December 31, 2023	1,266	1,265
Additional paid-in capital	28,725,509	28,160,745
Retained earnings	47,394,687	43,258,154
Total Stockholders' Equity	76,121,462	71,420,164
Total liabilities and stockholders' equity	$ 88,014,180	$ 92,156,098

About iRadimed Corp

IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices, and related accessories and services in the United States and internationally. It offers MRidium MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; and MRI compatible patient vital signs monitoring system. The company also provides non-magnetic IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring with sensors and accessories. It serves hospitals, acute care facilities, and outpatient imaging centers. The company sells its products through direct field sales representatives, regional sales directors, clinical support representatives, and independent distributors. IRADIMED CORPORATION was incorporated in 1992 and is headquartered in Winter Springs, Florida.

CEO	Mr. Roger E. Susi
WEBSITE	iradimed.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	123

iRadimed Corp Frequently Asked Questions

What is the ticker symbol for iRadimed Corp? What does IRMD stand for in stocks?

IRMD is the stock ticker symbol of iRadimed Corp. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of iRadimed Corp (IRMD)?

As of Fri May 17 2024, market cap of iRadimed Corp is 531.77 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of IRMD stock?

You can check IRMD's fair value in chart for subscribers.

What is the fair value of IRMD stock?

You can check IRMD's fair value in chart for subscribers. The fair value of iRadimed Corp is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of iRadimed Corp is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for IRMD so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is iRadimed Corp a good stock to buy?

The fair value guage provides a quick view whether IRMD is over valued or under valued. Whether iRadimed Corp is cheap or expensive depends on the assumptions which impact iRadimed Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for IRMD.

What is iRadimed Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, IRMD's PE ratio (Price to Earnings) is 29.67 and Price to Sales (PS) ratio is 7.86. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. IRMD PE ratio will change depending on the future growth rate expectations of investors.